Goldman Sachs
DSGN icon

Goldman Sachs’s Design Therapeutics DSGN Stock Holding History

Goldman Sachs’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.5M Buy
656,584
+151,866
+30% +$1.89M ﹤0.01% 3284
2026
Q1 		$5.37M Buy
504,718
+234,064
+86% +$2.37M ﹤0.01% 3623
2025
Q4 		$2.54M Buy
270,654
+9,209
+4% +$72.1K ﹤0.01% 4363
2025
Q3 		$1.97M Buy
261,445
+21,986
+9% +$110K ﹤0.01% 4494
2025
Q2 		$807K Sell
239,459
-26,557
-10% -$99.4K ﹤0.01% 4849
2025
Q1 		$1.03M Sell
266,016
-31,113
-10% -$148K ﹤0.01% 4671
2024
Q4 		$1.83M Buy
297,129
+21,597
+8% +$125K ﹤0.01% 4361
2024
Q3 		$1.48M Sell
275,532
-328,173
-54% -$1.54M ﹤0.01% 4382
2024
Q2 		$2.02M Buy
603,705
+97,449
+19% +$380K ﹤0.01% 3906
2024
Q1 		$2.04M Sell
506,256
-517,467
-51% -$1.38M ﹤0.01% 3850
2023
Q4 		$2.71M Buy
1,023,723
+579,225
+130% +$1.33M ﹤0.01% 3683
2023
Q3 		$1.05M Sell
444,498
-2,918
-0.7% -$13.6K ﹤0.01% 4240
2023
Q2 		$2.82M Buy
447,416
+146,792
+49% +$898K ﹤0.01% 3606
2023
Q1 		$1.73M Buy
300,624
+26,153
+10% +$196K ﹤0.01% 3970
2022
Q4 		$2.82M Sell
274,471
-719,174
-72% -$9.75M ﹤0.01% 3661
2022
Q3 		$16.6M Buy
993,645
+902,408
+989% +$18M ﹤0.01% 2037
2022
Q2 		$1.28M Sell
91,237
-25,895
-22% -$350K ﹤0.01% 4424
2022
Q1 		$1.89M Buy
117,132
+49,294
+73% +$755K ﹤0.01% 4314
2021
Q4 		$1.45M Buy
67,838
+12,704
+23% +$218K ﹤0.01% 4524
2021
Q3 		$810K Buy
55,134
+34,056
+162% +$566K ﹤0.01% 4906
2021
Q2 		$419K Sell
21,078
-62,372
-75% -$1.57M ﹤0.01% 5312
2021
Q1 		$2.5M Buy
+83,450
New +$2.81M ﹤0.01% 3768

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs's DSGN Position: Q2 2026 in Review

Goldman Sachs increased its Design Therapeutics (DSGN) stake by 30% in Q2 2026, buying an estimated $1.89M and bringing the position to 656,584 shares worth $9.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3284.

Goldman Sachs first reported a position in DSGN in Q1 2021 and has held it in 22 quarters since. The position peaked at $16.6M in Q3 2022. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Goldman Sachs held 656,584 shares of Design Therapeutics worth $9.5M as of Q2 2026.
  • Goldman Sachs bought 151,866 Design Therapeutics shares in Q2 2026, an estimated $1.89M.
  • Design Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3284 holding.
  • Goldman Sachs first reported a position in Design Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Goldman Sachs's Design Therapeutics position peaked at $16.6M in Q3 2022.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.